Live–Postbiotic Multistrain Platform for Immune-Response Regulation and Barrier Restoration in Experimental Colitis

Anas Ziraoui; Frederick Hollingsworth; Dylan Foster

doi:10.62051/ijphmr.v6n4.16

Authors

Anas Ziraoui
Frederick Hollingsworth
Dylan Foster

DOI:

https://doi.org/10.62051/ijphmr.v6n4.16

Keywords:

BALIMONT, Lactobacillus acidophilus, Lactobacillus plantarum, Bifidobacterium longum, Postbiotics, Ulcerative colitis, Immune regulation, Intestinal barrier

Abstract

We evaluated a BALIMONT live–postbiotic multistrain platform centered on Lactobacillus acidophilus ATCC 4356, Lactobacillus plantarum DSM 20174, and Bifidobacterium longum DSM 20219 for immune-response regulation and attenuation of experimental colitis. The live fraction was balanced at a viable-count ratio of 2:3:5 and paired with homologous postbiotic fractions at a live-bacteria-to-postbiotic mass ratio of 1:2. In the preclinical dataset retained in this manuscript, three BALIMONT variants were compared with a live-bacteria-only formulation in a DSS-induced colitis model. Across the BALIMONT variants, total inflammatory-burden reduction reached 65.7%–68.2%, whereas the live-bacteria-only comparator achieved 32.5%; tight-junction protein upregulation reached 40.1%–42.6% versus 18.3%, respectively. To place these findings in clinical context, we reviewed published randomized and controlled human studies of probiotics, synbiotics, and related microbiota-directed therapies in ulcerative colitis. Human trials involving Bifidobacterium longum, Bifidobacterium breve, Lactobacillus acidophilus-containing combinations, and Escherichia coli Nissle 1917 have reported improvements in sigmoidoscopy or endoscopy, disease-activity indices, mucosal inflammatory signaling, or remission-related outcomes, although effect sizes were strongly formulation- and strain-dependent. Taken together, our retained preclinical results and the published clinical literature support the translational plausibility of a live–postbiotic strategy for immune modulation and barrier restoration, while also showing that exact-strain clinical confirmation remains necessary.

References

[1] Salminen S, Collado MC, Endo A, et al. The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics. Nat Rev Gastroenterol Hepatol. 2021; 18(9):649-667. doi:10.1038/s41575-021-00440-6.

[2] Gutzeit C, Magri G, Cerutti A. Intestinal IgA production and its role in host-microbe interaction. Immunol Rev. 2014; 260(1):76-85. doi:10.1111/imr.12189.

[3] Hu T, Wang H, Xiang Y, et al. Preventive effect of Lactobacillus acidophilus XY27 on DSS-induced ulcerative colitis in mice. Drug Des Devel Ther. 2020; 14:5977-5991.

[4] Wang H, Sun Y, Ma X, et al. The Lactobacillus plantarum P-8 probiotic microcapsule prevents DSS-induced colitis through improving intestinal integrity and reducing colonic inflammation in mice. Nutrients. 2024; 16(7):1055. doi:10.3390/nu16071055.

[5] Li M, Ding J, Stanton C, et al. Bifidobacterium longum subsp. infantis FJSYZ1M3 ameliorates DSS-induced colitis by maintaining the intestinal barrier, regulating inflammatory cytokines, and modifying gut microbiota. Food Funct. 2023; 14(1):354-368. doi:10.1039/D2FO03263E.

[6] Furrie E, Macfarlane S, Kennedy A, et al. Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Gut. 2005; 54(2):242-249. doi:10.1136/gut.2004.044834.

[7] Cui HH, Chen CL, Wang JD, et al. Effects of probiotic on intestinal mucosa of patients with ulcerative colitis. World J Gastroenterol. 2004; 10(10):1521-1525. doi:10.3748/wjg.v10.i10.1521.

[8] Ishikawa H, Matsumoto S, Ohashi Y, et al. Beneficial effects of probiotic bifidobacterium and galacto-oligosaccharide in patients with ulcerative colitis: a randomized controlled study. Digestion. 2011; 84(2):128-133. doi:10.1159/000322977.

[9] Wildt S, Nordgaard I, Hansen U, Brockmann E, Rumessen JJ. A randomised double-blind placebo-controlled trial with Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis BB-12 for maintenance of remission in ulcerative colitis. J Crohns Colitis. 2011; 5(2):115-121. doi:10.1016/j.crohns.2010.11.004.

[10] Tamaki H, Nakase H, Inoue S, et al. Efficacy of probiotic treatment with Bifidobacterium longum 536 for induction of remission in active ulcerative colitis: a randomized, double-blinded, placebo-controlled multicenter trial. Dig Endosc. 2016; 28(1):67-74. doi:10.1111/den.12553.

[11] Park SK, Hong H, Oh K, et al. Additive effect of probiotics (Mutaflor) on 5-aminosalicylic acid therapy in patients with ulcerative colitis. Korean J Intern Med. 2022; 37(5):949-957. doi:10.3904/kjim.2021.458.

[12] Estevinho MM, González-Martínez C, María N, et al. Efficacy and safety of probiotics in IBD: An overview of systematic reviews and updated meta-analysis of randomized controlled trials. United European Gastroenterol J. 2024; 12(8):960-977. doi:10.1002/ueg2.12654.

[13] Huang C, Fan L, Hu B, et al. Probiotics for the treatment of ulcerative colitis: a review of experimental research from 2018 to 2022. Front Microbiol. 2023; 14:1211271. doi:10.3389/fmicb.2023.1211271.